Metsera
About Metsera
Metsera develops oral and injectable therapies targeting obesity and metabolic diseases, utilizing proprietary health technology tools for personalized treatment and risk prediction. The company aims to alleviate the physical, emotional, and economic burdens associated with obesity, providing effective and scalable solutions for weight management.
```xml <problem> Obesity and related metabolic diseases pose significant physical, emotional, and economic burdens, yet current therapies often lack the desired balance of efficacy, tolerability, convenience, and scalability. Existing treatments may present barriers to adoption and long-term adherence, hindering effective weight management and overall health improvement. </problem> <solution> Metsera is a clinical-stage biotechnology company focused on developing a new generation of nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases. Their portfolio includes both injectable and oral therapeutic candidates engineered for improved potency, durability, bioavailability, and manufacturability. Metsera's integrated approach spans peptide engineering, translational science, clinical development, and large-scale manufacturing, with the goal of delivering continuous innovation in the obesity treatment landscape. The company leverages proprietary health technology tools for personalized treatment strategies and risk prediction, aiming to optimize weight management and address obesity-related conditions. By focusing on scalable and convenient therapies, Metsera seeks to reduce barriers to adoption and improve long-term patient outcomes. </solution> <features> - Oral and injectable therapeutic candidates targeting obesity and related metabolic diseases - Proprietary peptide engineering platform for enhanced potency, durability, and bioavailability - Nutrient-stimulated hormone (NuSH) therapies designed to mimic natural physiological processes - Integrated approach spanning peptide engineering, translational science, and clinical development - Proprietary health technology tools for personalized treatment and risk prediction - Scalable manufacturing processes to ensure widespread availability of therapies </features> <target_audience> Metsera's primary target audience includes individuals with obesity and related metabolic diseases, as well as healthcare providers specializing in weight management and metabolic disorders. </target_audience> ```
What does Metsera do?
Metsera develops oral and injectable therapies targeting obesity and metabolic diseases, utilizing proprietary health technology tools for personalized treatment and risk prediction. The company aims to alleviate the physical, emotional, and economic burdens associated with obesity, providing effective and scalable solutions for weight management.
Where is Metsera located?
Metsera is based in East New York, United States.
When was Metsera founded?
Metsera was founded in 2022.
How much funding has Metsera raised?
Metsera has raised 215000000.
- Location
- East New York, United States
- Founded
- 2022
- Funding
- 215000000
- Employees
- 68 employees
- Major Investors
- Wellington Management, Venrock Healthcare Capital Partners